Assembly Biosciences (NASDAQ:ASMB) Announces Quarterly Earnings Results

Assembly Biosciences (NASDAQ:ASMB) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.52, FiscalAI reports. The business had revenue of $13.37 million for the quarter, compared to the consensus estimate of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%.

Assembly Biosciences Trading Up 10.0%

Shares of NASDAQ:ASMB opened at $32.95 on Friday. Assembly Biosciences has a 12-month low of $20.23 and a 12-month high of $39.71. The business has a 50 day moving average of $26.09 and a two-hundred day moving average of $27.38. The company has a market capitalization of $523.58 million, a PE ratio of 32.30 and a beta of 1.10.

Institutional Trading of Assembly Biosciences

Hedge funds have recently added to or reduced their stakes in the company. Barclays PLC increased its holdings in Assembly Biosciences by 524.6% in the fourth quarter. Barclays PLC now owns 24,741 shares of the biopharmaceutical company’s stock valued at $841,000 after buying an additional 20,780 shares in the last quarter. ADAR1 Capital Management LLC boosted its stake in shares of Assembly Biosciences by 4.2% during the 4th quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock worth $672,000 after acquiring an additional 800 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Assembly Biosciences during the 3rd quarter worth about $553,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Assembly Biosciences during the 4th quarter valued at about $530,000. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of Assembly Biosciences during the 4th quarter valued at about $512,000. 19.92% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Mizuho set a $45.00 target price on shares of Assembly Biosciences and gave the stock an “outperform” rating in a research note on Monday, June 15th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Assembly Biosciences in a report on Monday, May 4th. Guggenheim restated a “buy” rating and issued a $43.00 price objective on shares of Assembly Biosciences in a research note on Thursday, May 28th. Wall Street Zen downgraded Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Friday, July 17th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $44.00.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.